DaxibotulinumtoxinA is under clinical development by Revance Therapeutics and currently in Phase II for Upper Limb Muscle Spasticity. According to GlobalData, Phase II drugs for Upper Limb Muscle Spasticity have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DaxibotulinumtoxinA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DaxibotulinumtoxinA overview

DaxibotulinumtoxinA-lanm (Daxxify) is a 150 kDa botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A. It is formulated as lyophilized powder for solution for intramuscular and subcutaneous route of administration. Daxxify is indicated for the treatment of cervical dystonia in adult patients.
RT-002 is under development for the treatment of spasmodic torticollis (cervical dystonia), upper limb spasticity and chronic migraine. It is administered through intramuscular and parenteral route. The drug candidate is an injectable neurotoxin, purified botulinum toxin type A that targets synaptosomal-associated protein 25. It is being developed based on TransMTS peptide technology.
The drug candidate was under development for the treatment of plantar fasciitis and voice disorders.

Revance Therapeutics overview

Revance Therapeutics is a biotechnology company that focuses on the development, manufacturing and marketing novel botulinum toxin products. Its approved products are daxibotulinumtoxinA-lanm injection (DAXI) for two conditions cervical dystonia and glabellar (frown) lines. It is investigating its lead candidate, daxibotulinumtoxinA, a topical gel formulation as a needle-free approach for a wide range of therapeutic and aesthetic indications, such as chronic migraine, facial wrinkles and muscle disorders. The company is also advancing daxibotulinumtoxinA for injection (DAXI), an injectable formulation of botulinum toxin for the treatment of glabellar lines, cervical dystonia and plantar fasciitis. It employs its proprietary peptide excipient technology to advance the development of its novel neuromodulators portfolio. Revance Therapeutics is headquartered in Nashville, Tennessee, the US.

For a complete picture of DaxibotulinumtoxinA’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.